Biocon Partners With Biotech Startup In Latest India-U.S. Deal
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Biocon, India's largest biotechnology company, said it would list its Syngene research service unit next financial year and make a "strategic" investment in U.S. firm IATRICa to co-develop a new class of immunoconjugates that provides targeted immunotherapy for cancers and infectious diseases
You may also be interested in...
India’s Biocon Moves Forward With Oral Insulin After Encouraging Phase II Results
MUMBAI - In what is seen as a significant development for the company, Indian biotechnology firm Biocon presented encouraging Phase II data on its experimental oral insulin drug coded IN-105 at the European Association for the Study of Diabetes meeting being held at Rome
India’s Biocon Moves Forward With Oral Insulin After Encouraging Phase II Results
MUMBAI - In what is seen as a significant development for the company, Indian biotechnology firm Biocon presented encouraging Phase II data on its experimental oral insulin drug coded IN-105 at the European Association for the Study of Diabetes meeting being held at Rome
India's Biocon Issues One-For-One Bonus Shares, Says Acquisitions, New Drug Development To Drive Earnings
BANGALORE, India - India's largest biotechnology drug firm Biocon said clinical trials for diabetes, psorasis, arthritis and cancer drugs are progressing and it plans to launch a new cardio-diabetes division to focus on brand building for its statin Statix (atorvastatin)